Compare WINA & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WINA | SNDX |
|---|---|---|
| Founded | 1988 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 1993 | 2016 |
| Metric | WINA | SNDX |
|---|---|---|
| Price | $426.96 | $20.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $36.92 |
| AVG Volume (30 Days) | 84.2K | ★ 2.4M |
| Earning Date | 10-15-2025 | 11-03-2025 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | ★ 2.56 | N/A |
| EPS | ★ 11.21 | N/A |
| Revenue | $84,517,400.00 | ★ $111,304,000.00 |
| Revenue This Year | $7.05 | $620.14 |
| Revenue Next Year | $3.60 | $115.42 |
| P/E Ratio | $38.01 | ★ N/A |
| Revenue Growth | 3.35 | ★ 595.65 |
| 52 Week Low | $295.79 | $8.58 |
| 52 Week High | $527.37 | $20.59 |
| Indicator | WINA | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 51.25 | 69.27 |
| Support Level | $405.86 | $18.36 |
| Resistance Level | $432.21 | $20.20 |
| Average True Range (ATR) | 15.68 | 0.98 |
| MACD | 2.91 | 0.15 |
| Stochastic Oscillator | 68.18 | 92.43 |
Winmark Corp is a franchisor of value-oriented retail store concepts that buy, sell, and trade gently used merchandise. The company has one reportable segment including Franchising and one non-reportable segment Leasing. The franchising segment franchises value-oriented retail store that buys, sell, trade, and consign merchandise as well as provide strategic consulting services relating to franchising. The leasing segment includes middle-market equipment leasing business and small-ticket financing business. It generates a majority of its revenue from the Franchising segment.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.